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Dual Topology of the Melanocortin-2 
receptor accessory Protein is stable
Zachary J. Maben, Sundeep Malik, Liyi H. Jiang and Patricia M. Hinkle*
Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, USA
Melanocortin 2 receptor accessory protein (MRAP) facilitates trafficking of melanocortin 2 
(MC2) receptors and is essential for ACTH binding and signaling. MRAP is a single trans-
membrane domain protein that forms antiparallel homodimers. These studies ask when 
MRAP first acquires this dual topology, whether MRAP architecture is static or stable, and 
whether the accessory protein undergoes rapid turnover. To answer these questions, we 
developed an approach that capitalizes on the specificity of bacterial biotin ligase, which 
adds biotin to lysine in a short acceptor peptide sequence; the distinct mobility of MRAP 
protomers of opposite orientations based on their N-linked glycosylation; and the ease 
of identifying biotin-labeled proteins. We inserted biotin ligase acceptor peptides at the 
N- or C-terminal ends of MRAP and expressed the modified proteins in mammalian cells 
together with either cytoplasmic or endoplasmic reticulum-targeted biotin ligase. MRAP 
assumed dual topology early in biosynthesis in both CHO and OS3 adrenal cells. Once 
established, MRAP orientation was stable. Despite its conformational stability, MRAP 
displayed a half-life of under 2 h in CHO cells. The amount of MRAP was increased 
by the proteasome inhibitor MG132 and MRAP underwent ubiquitylation on lysine and 
other amino acids. Nonetheless, when protein synthesis was blocked with cyclohexim-
ide, MRAP was rapidly degraded even when MG132 was included and all lysines were 
replaced by arginines, implicating non-proteasomal degradation pathways. The results 
show that although MRAP does not change orientations during trafficking, its synthesis 
and degradation are dynamically regulated.
Keywords: accessory protein, acTh, biotin ligase, caMP, Mc2 receptor, MraP, membrane protein topology, 
ubiquitin
inTrODUcTiOn
The hypothalamic/pituitary/adrenal axis comprises a classical endocrine loop in which hypotha-
lamic corticotropin-releasing hormone stimulates synthesis and release of ACTH from corticotropes 
of the anterior pituitary gland, ACTH stimulates glucocorticoid production in the adrenal gland, 
and glucocorticoids exert feedback control centrally. ACTH stimulates multiple steps in the glu-
cocorticoid biosynthetic pathway, acting via a receptor coupled to the heterotrimeric Gs protein to 
activate adenylyl cyclase and elevate intracellular cAMP. ACTH also exerts receptor-dependent but 
cAMP-independent effects (1).
Abbreviations: AP, acceptor peptide; BirAcyt, cytoplasmic biotin ligase; BirAER, ER-targeted biotin ligase-KDEL; Ccyt, cyto-
plasmic carboxyterminus; Cexo, extracellular carboxyterminus; CRE, cAMP response element; ER, endoplasmic reticulum; 
MC2R, melanocortin-2 receptor; MRAP, MC2 receptor accessory protein; Ncyt, intracellular aminoterminus; Nexo, extracel-
lular aminoterminus.
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The receptor for ACTH was identified almost 25 years ago by 
Mountjoy et al. (2). The melanocortin 2 (MC2) (ACTH) receptor 
is one of five structurally related G protein-coupled melanocortin 
receptors, MC1 through MC5, all of which are activated by pep-
tides derived from pro-opiomelanocortin, or POMC. The MC2 
receptor was found to differ from the other four melanocortin 
receptors in two important ways. First, it could not be activated 
by α-, β-, or γ-MSH but only by the longer ACTH peptide. 
Second, it was not functional unless it was expressed in adrenal 
or melanoma cells. This led to speculation that the MC2 receptor 
required an additional protein present in a limited number of 
cell types.
The nature of the hypothetical accessory protein remained a 
mystery for more than a decade, when Metherell et al. (3) identi-
fied the gene encoding MC2 receptor accessory protein (MRAP) 
from individuals with familial glucocorticoid deficiency type 2, 
which is characterized by resistance to ACTH despite normal 
MC2 receptor genes. MRAP encodes a small protein with a 
single predicted transmembrane domain. Two splice variants 
of human MRAP (α and β) are identical in the aminoterminal 
and transmembrane regions. When MRAP was co-expressed 
with MC2 receptor, the receptor was able to traffic to the plasma 
membrane and respond to ACTH with an increase in cAMP in 
cells that were otherwise non-responsive. MRAP and MC2 recep-
tors have been shown to interact closely by a variety of approaches 
including  co-precipitation (4, 5), fluorescence microscopy (6, 7), 
bimolecular fluorescence complementation (8), and co-inter-
nalization in response to ACTH (9). Recent data establish that 
two MRAP dimers can interact with one MC2 receptor and that 
two MC2 receptors can interact with one MRAP, but it is unclear 
whether this happens normally (10). MRAP2, an MRAP paralog, 
 co-precipitates with the MC2 receptor and all other members of 
the melanocortin receptor family (5) but does not support signal-
ing by MC2 receptors (11).
Using an alanine-scanning mutagenesis approach and 
focusing on the highly conserved aminoterminus of MRAP, we 
discovered that MRAP lacking a critical tyrosine-rich region 
was able to promote MC2 receptor trafficking but not signaling 
(11). This established that MRAP has two distinct functions, one 
to enable MC2 receptor trafficking to the cell surface, perhaps 
because it assists protein folding, and a second to enable signal 
transduction. Importantly, when MC2 receptors were expressed 
with a mutated MRAP, receptors were localized on the plasma 
membrane but completely unable to bind ACTH. As a result, 
ACTH cannot be expected to exert any effect – cAMP-dependent 
or otherwise – in cells lacking MRAP.
It is well established that mRNA encoding MC2 receptor 
undergoes feed-forward regulation, increasing in response to 
stress or ACTH (12). MRAP mRNA levels also increase, and 
do so within minutes, in response to either an imposed stress 
or ACTH (13, 14). MC2 receptor and MRAP mRNAs rise dra-
matically when cultured adrenal cells are incubated with ACTH, 
establishing a direct action at the adrenal gland (15). It is not 
known whether MC2 receptor and MRAP protein levels also 
change on a rapid time scale. One of the goals of the experiments 
described here was to characterize MRAP turnover in an isolated 
cell system.
The architecture of MRAP is extremely unusual. MRAP appears 
to form antiparallel homodimers. This conclusion is based on the 
following: (1) immunological findings showing dual topology, 
where antibodies identify both the amino and carboxyterminal 
ends of MRAP facing outwards on the cell surface (4); (2) quan-
titative co-precipitation of differentially tagged MRAPs, pointing 
to a multimeric structure (4); (3) biochemical experiments show-
ing that approximately half of MRAP undergoes glycosylation at 
the single predicted site for N-linked glycosylation, a process that 
takes place in the interior of the endoplasmic reticulum (ER) and 
Golgi apparatus (4); (4) bimolecular fluorescence complementa-
tion (8) and bioluminescence resonance energy transfer (16) in 
configurations consistent with an antiparallel dimeric structure; 
and (5) evidence that a concatenated protein made by fusing two 
MRAPs to the extracellular aminoterminus of the MC2 receptor 
is ACTH-responsive (10). The latter studies established that the 
tyrosine-rich domain of the MRAP aminoterminus is necessary 
on the outer surface of the cell, likely allowing ACTH to bind.
Taken together, these data provide strong evidence that MRAP 
forms antiparallel homodimers. MRAP and MRAP2 are the only 
single transmembrane domain proteins thought to exist in this 
configuration. It is not yet known when MRAP conformation is 
established, whether MRAP orientation changes during synthesis 
and trafficking, whether dual topology predominates in adrenal 
cells, and whether MRAP is stable. We designed the experiments 
reported here to address these unresolved issues and describe 
several approaches to probe the topology of the MRAP protein at 
different times after biosynthesis and estimate its half-life.
MaTerials anD MeThODs
reagents
Melanocortin 2 receptor accessory protein plasmids that have 
not been described previously (4, 8, 11) were constructed using 
QuikChange from Stratagene with standard molecular biologi-
cal techniques and verified by sequencing. MRAP–V5–3xFlag 
contained mMRAP followed by GKPIPNPLLGLDSTGRDY 
KDHDGDYKDHDIDYKDDDDK at the C-terminus. AP–MRAP 
contained the minimal AP sequence GLNDIFEAQKIEWHE 
immediately after the initiating Met followed by mMRAP 
or mMRAP–V5–3xFlag. MRAP–AP contained the same AP 
sequence at the C-terminus of mMRAP or mMRAP–V5–3xFlag 
followed by a stop codon. MRAPs containing the AP sequence but 
no epitope tags were constructed similarly. On figures, these con-
structs are shown as AP–MRAP or MRAP–AP and epitope tags are 
described in the legends. V5–MART1–AP and AP–MART1–V5 
were constructed by adding V5 epitope (GKPIPNPLLGLDST) 
and AP sequence (GLNDIFEAQKIEWHE) to opposite ends of 
mMART1. (4K to R)MRAP refers to V5–mMRAP–3xFlag with 
the four Lys in native mMRAP mutated to Arg. 3xHA-hMC2 
receptor, referred to as MC2 receptor, was from Missouri cDNA 
Resource Center and plasmid encoding eGFP from Clontech. 
BirA in pcDNA3 and BirAER in pDisplay vectors were gener-
ously donated by Dr. Alice Ting (Massachusetts Institute of 
Technology) and CRE-luciferase by Dr. George Holz (SUNY 
Upstate Medical University). Plasmid encoding HA-ubiquitin 
(HA-Ub) has been described (17). Monoclonal antibodies were 
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from the following: Sigma (M2 anti-Flag and immobilized M2 
anti-Flag), Covance (HA-11 anti-HA), and AbDSerotec (anti-
V5). Streptavidin–HRP and streptavidin–agarose were from 
Thermo Scientific, immobilized Protein A/G beads from Santa 
Cruz Biotechnology, and HRP-labeled antibody against mouse 
heavy and light chains from BioRad.
cell growth and Transfection
CHO cells were from American Type Culture Collection and 
OS3 adrenal cells (18) from Dr. Bernard Schimmer (University 
of Toronto). CHO and OS3 cells were maintained in DMEM/
F12 medium containing 5% fetal bovine serum at 37°C in 5% 
CO2-95% air and passaged with trypsin. Transfection was per-
formed using FugeneHD or Lipofectamine 3000 according to 
manufacturers’ instructions. Stable cell lines were generated by 
transfecting with plasmids encoding an MRAP, BirA, or BirAER 
and selecting with 1  mg/ml G418. Pooled cells were used for 
experiments. Biotin-labeling experiments were performed by 
adding 2.5 μM biotin to complete medium at the time of trans-
fection unless otherwise noted.
caMP responses
In brief, cells were grown in white 96-well plates and transfected 
with 40–50 ng total DNA/well, usually with equal parts of MC2 
receptor, MRAP construct and CRE-luciferase, a reporter con-
taining multiple cAMP response elements from the rat insulin 
promoter (19). After 24 h cells were challenged for 4–5 h with 
hACTH(1–24) or 20 μM forskolin in DMEM with 0.1% BSA. 
Medium was replaced with Firefly Reagent from Nanolight and 
luminescence read in a BioTek platereader. Unless noted, results 
are expressed as percent of the forskolin response measured in 
the same experiment.
immunoprecipitation, sDs-Page,  
and immunoblotting
Cells were washed with PBS and lysed on ice in Tris/Mg/
EGTA buffer (150  mM NaCl, 50  mM Tris-Cl, 1  mM EDTA, 
and 1% Triton X-100, pH 8.0) containing protease inhibitors. 
Iodoacetamide (10  mM) was included in lysis buffers when 
ubiquitin labeling was being assessed. Samples were centrifuged 
at 10,000  ×  g for 20  min to remove nuclei and supernatants 
used for analysis. In some cases, HA- or Flag-labeled proteins 
were immunoprecipitated by incubating overnight at 4°C with 
1:1000 dilutions of antibody and collected on Protein A/G beads. 
Biotin-labeled proteins were pelleted following overnight incuba-
tion with streptavidin–agarose beads. Samples were taken up in 
NuPage LDS sample buffer with a final concentration of 50 mM 
dithiothreitol. For analysis by SDS-PAGE samples were run on 
Lonza PagR or BioRad TGX gels. Proteins were transferred to 
nitrocellulose, blocked in TBST (Tris-buffered saline with 0.05% 
Tween 20) with 5% non-fat dry milk, and incubated overnight at 
4°C in either monoclonal anti-V5, anti-HA, or anti-Flag antibody 
at 1:5000 in TBST/milk. After washing, antibody blots were incu-
bated in 1:5000 HRP-anti-mouse heavy and light chain, washed 
and visualized using Western Lightning chemiluminescent rea-
gent. To visualize biotin-labeled proteins, blots were incubated in 
1:10,000 HRP–streptavidin in TBST with 0.5–1% BSA, because 
milk contains biotin, washed and developed. In some cases, blots 
were subsequently incubated in 0.1% sodium azide to inactivate 
HRP and blotted with antibody as described above.
cell surface elisa
Expression of proteins on the plasma membrane was quantified 
as described previously (4, 11). Cells grown in 12- or 24-well 
plates were fixed with 2 or 3% paraformaldehyde for 10–20 min at 
room temperature, washed with PBS, and incubated for ~1 h with 
1:5000 monoclonal anti-HA, anti-V5, or anti-Flag antibodies in 
PBS containing 5% non-fat dry milk. Cells were then washed 
extensively and incubated for ~1  h with 1:5000 HRP-labeled 
anti-mouse IgG, and washed prior to the addition of tetrameth-
ylbenzidine substrate (Sigma) and measurement of absorbance 
at 450 nm.
Fluorescence Microscopy
For microscopy, CHO cells stably expressing BirAcyt or BirAER 
were grown on glass coverslips and transfected with AP-tagged 
MRAP constructs. After overnight incubation, live cells were 
incubated with anti-Flag antibody (1:250 in serum-containing 
medium) for 30 min at 37°C, washed, and then incubated with 
1:500 Alexa488-labeled anti-mouse M2 and 1:500 Alexa555-
labeled streptavidin and incubated for 30  min at room tem-
perature. Cells were washed, fixed in paraformaldehyde, washed 
again and mounted in Prolong Gold (InVitrogen), and viewed 
in a Nikon epifluorescence microscope with a 40× oil objective. 
Images showing Flag and streptavidin were obtained using 500 
and 2500 ms exposures, respectively. All Flag and all streptavidin 
micrographs were processed identically.
Miscellaneous
To deglycosylate proteins, cell lysates were denatured and incu-
bated with PNGaseF from New England Biolabs following manu-
facturer’s instructions; control lysates were incubated identically 
in reactions lacking enzyme. All experiments were repeated 
a minimum of two times. Error bars indicate mean and range 
or SE of duplicate or triplicate determinations in representative 
experiments. Significance of differences between two values was 
determined by Student’s t-test.
resUlTs
When is MraP Topology established?
The strategy used to determine whether MRAP is first synthesized 
in dual orientations is outlined schematically in Figure 1A. Biotin 
labeling of a protein modified to contain a decarboxylase biotin 
acceptor domain was used previously to characterize membrane 
insertion of bacterial lactose permease (20). The biotin-labeling 
approach described here uses a small acceptor sequence and 
exogenous BirAs to provide a new means to analyze MRAP 
architecture. The bacterial enzyme biotin ligase (BirA) attaches 
a biotin residue to the single Lys residue in a specific acceptor 
peptide sequence (AP). When expressed in mammalian cells, 
bacterial biotin ligase is localized in the cytoplasm; addition of 
a carboxyterminal KDEL sequence targets the enzyme to the 
ER (21, 22). Because there are relatively low concentrations of 
AB
FigUre 1 | Use of biotin tagging to discern MraP orientation. (a) Schematic representation showing the sequence of the acceptor peptide (AP) for bacterial 
biotin ligase that catalyzes addition of biotin to Lys. Addition of C-terminal KDEL sequence to BirA targets it to the ER. Circles depict a potential N-linked 
glycosylation site (Asn-X-Ser/Thr) with or without glycosylation. An AP sequence was added immediately after the initiating Met in AP–MRAP or at the C-terminus in 
MRAP–AP as detailed in Section “Materials and Methods.” (B) ACTH responses of CHO cells expressing a cAMP-responsive CRE-luciferase reporter, MC2 receptor, 
and MRAP constructs.
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biotin in standard serum-supplemented tissue culture media, it is 
straightforward to initiate biotin labeling of a protein tagged with 
an AP sequence by adding exogenous biotin. Mouse MRAP con-
tains a single N-linked glycosylation site at Asn3 of the aminoter-
minus and N-glycosylation occurs exclusively in the inside of the 
ER and Golgi apparatus, which is topologically equivalent to the 
exoplasmic face of the plasma membrane. Glycosylated MRAP, 
which migrates more slowly than non-glycosylated MRAP on 
SDS-PAGE, must, therefore, be in the Nexo/Ccyt orientation unless 
it has changed orientations during trafficking. We engineered 
MRAPs with an AP sequence at either the aminoterminal or car-
boxyterminal end of the protein; each of these MRAP constructs 
also contained a Flag epitope. As shown in Figure 1B, control 
MRAP, AP–MRAP (N-terminal AP sequence), and MRAP–AP 
(C-terminal AP sequence) all supported comparable ACTH-
stimulated increases in a cAMP reporter.
MRAP, AP–MRAP, and MRAP–AP were expressed in CHO 
cells stably expressing either cytoplasmic BirA or ER-targeted 
BirAER. The upper left panel of Figure 2 shows a Flag immunoblot 
identifying total MRAP. In every case, monomeric glycosylated 
and non-glycosylated MRAP species ran as a doublet at ~20 and 
25  kDa. Enzymatic degradation with the glycosidase PNGaseF 
confirmed that the two major bands represented MRAP with and 
without N-linked glycosylation (4) and Figure 11 below. Higher 
MW bands are likely MRAP multimers and their mobility shifts 
following PNGaseF treatment (not shown). The upper right panel 
of Figure  2A shows the same blot probed with streptavidin to 
detect only biotin-labeled proteins. Despite having identical 
molecular weights, AP–MRAP and MRAP–AP consistently 
displayed different mobilities on SDS-PAGE, as do AP–MART1 
and MART1–AP (Figure 3 below). It is possible that the proteins 
undergo different post-translational modifications but the behav-
ior of membrane proteins on SDS-PAGE is not always predictable.
Endogenous biotinylated carboxylases are visible in all lanes 
at high molecular weight (75 kDa and above) in the blot on the 
upper right. These metabolically labeled proteins do not depend 
on transfected BirA. The three control lanes shown on the left 
of each blot in Figure  2 demonstrate that MRAP lacking the 
biotin acceptor peptide was expressed well but not labeled with 
biotin. Cytoplasmic BirA catalyzed the addition of biotin to the 
faster-migrating, non-glycosylated form of AP–MRAP (situa-
tion a in Figure 2B), whereas ER-targeted BirAER added biotin 
to the higher molecular weight glycosylated form of AP–MRAP 
(situation b). The reverse was found when cytoplasmic BirA and 
ER-targeted BirAER were expressed with MRAP–AP. In this case, 
BirAcyt preferentially labeled glycosylated MRAP–AP and BirAER 
preferentially labeled non-glycosylated MRAP–AP (situations c 
and d, respectively). These results support the conclusion that 
the great majority of MRAP molecules achieve an antiparallel 
orientation when first synthesized. The finding of some biotin-
labeled but non-glycosylated AP–MRAP with BirAER could 
result from (1) biotin labeling of AP–MRAP that is incompletely 
glycosylated, (2) incomplete import of overexpressed BirAER into 
the ER leaving some active enzyme in the cytoplasm, or (3) a 
change in orientation of a small portion of MRAP after synthesis. 
The finding of a biotin-labeled and glycosylated MRAP–AP band 
with BirAER is consistent with incomplete BirAER import. After 
overnight incubation in biotin-supplemented media, essentially 
all AP-tagged MRAP could be collected on streptavidin–agarose 
beads, implying nearly quantitative biotinylation.
AB
FigUre 2 | Biotin labeling confirms dual topology of MraP. (a) CHO cells stably expressing BirAcyt or BirAER were transfected with MRAP, AP–MRAP, or 
MRAP–AP; these plasmids also contained a Flag epitope. Following detergent solubilization, proteins were resolved on SDS-PAGE and probed with monoclonal 
anti-Flag antibody and HRP-anti-mouse IgG or HRP–streptavidin. (B) Expected localization of BirA and predicted orientation of newly synthesized MRAPs. Filled and 
open circles depict glycosylated and non-glycosylated MRAP and red stars represent biotin.
5
Maben et al. Stability of MRAP Topology
Frontiers in Endocrinology | www.frontiersin.org July 2016 | Volume 7 | Article 96
As an additional control for this approach, we studied MART1 
(also called Melan-A), a melanosome protein with a single 
transmembrane domain, strongly predicted Nexo/Ccyt orientation, 
and size close to that of mouse MRAP (18 vs. 14 kDa without 
epitopes or carbohydrate). We engineered plasmids encoding 
MART1 with AP tags at one end or the other and V5 tags at the 
opposite ends. We used a previously described fixed cell ELISA 
protocol (4) in which antibodies were added to intact cells to 
detect epitopes localized on the outside of the plasma membrane 
(Figure 3A). MART1 was found in the predicted Nexo/Ccyt orien-
tation, whereas MRAPs with the AP sequence at either end were 
found in dual Nexo/Ccyt and Ncyt/Cexo orientations. MRAP but 
not MART1 increased surface expression of co-expressed MC2 
receptor (Figure 3B). MART1 was then tested in an experiment 
identical to that shown in Figure 2 for MRAP. AP–MART1 was 
expressed strongly but labeled only by ER-localized BirAER and 
labeling was rather weak (Figure 3C). By contrast, MART1–AP 
was expressed weakly but labeled strongly by cytoplasmic BirA 
and slightly by BirAER. Labeling by BirAER probably occurred 
because of incomplete import of BirAER into the ER, which left 
some biotin ligase in the cytoplasm.
Does MraP change Orientation 
after Biosynthesis?
To isolate MRAP that had trafficked to the plasma membrane, 
we localized cell surface biotin-labeled MRAP by fluorescence 
microscopy. Cells stably expressing cytoplasmic or ER-targeted 
BirA were transiently transfected to express either AP–MRAP–
Flag or MRAP–Flag–AP. After incubation with biotin, live cells 
were stained with monoclonal anti-Flag antibody or fluorescent 
streptavidin. Because MRAP forms an antiparallel structure, 
both AP–MRAP–Flag and MRAP–Flag–AP were detectable on 
the cell surface with anti-Flag antibody, as expected (Figure 4A). 
On the other hand, if AP–MRAP–Flag and MRAP–Flag–AP did 
not change orientations following biosynthesis, only ER-localized 
BirAER would be able to label acceptor peptide in the ER lumen 
and, after trafficking, the extracellular side of the plasma mem-
brane (Figure  4B). This result was obtained, with cell surface 
MRAP clearly labeled in all configurations but cell surface biotin-
labeled MRAP visible only in cells expressing BirAER. The results 
of this experiment are not confounded by incomplete import of 
BirAER into the ER.
A kinetic approach was also undertaken to determine whether 
MRAP changes orientation after biosynthesis (Figure  5). To 
avoid the ambiguity present in experiments using BirAER, cells 
were transfected with cytoplasmic BirA and either AP–MRAP 
or MRAP–AP and incubated overnight in the absence of added 
biotin. During this period MRAP synthesis took place with very 
little biotin labeling (zero time point). Cells were then treated 
with added biotin for times up to 24 h. Immunoblotting for total 
AP–MRAP and MRAP–AP with anti-Flag antibodies is shown 
in the left panels. As seen previously (Figure 2A), cytoplasmic 
AC
B
FigUre 3 | Biotin labeling confirms single orientation of a control 
protein. (a) CHO cells were transfected with plasmids encoding MRAP or 
MART1 with AP and V5 epitopes at the N- or C-terminus as shown. The 
topology prediction programs TMHMM and HMMTOP predict that both 
unmodified and epitope-tagged versions of MART1 will assume an 
exclusively Nexo orientation whereas MRAPs are likely to assume both Nexo 
and Ncyt orientations. (B) Cells were transfected with plasmids encoding 
HA-tagged MC2 receptor and MRAP or MART1 as in (a) and surface 
receptor was quantified. Expression of tagged proteins on the plasma 
membrane was measured as described in Section “Materials and Methods.” 
(c) Plasmids encoding MART1 tagged with AP at either the N- or C-terminus 
and V5 epitope at the opposite end were transfected into CHO cells stably 
expressing BirAcyt or BirAER. High MW bands seen in all lanes are endogenous 
biotinylated proteins. *P < 0.05; #P < 0.1.
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BirA labeled the faster-moving non-glycosylated AP–MRAP 
band. Increased biotin labeling could be detected as early as 6 min 
after biotin supplementation and labeling continued over time; 
after 24 h, there was only a trace amount of a higher molecular 
weight biotin-labeled AP–MRAP (Figure 5A). This result does 
not support the idea that MRAP flips orientations after synthesis. 
In the case of MRAP–AP, a minor fraction of non-glycosylated 
biotin-labeled MRAP was visible but the proportion did not 
increase with time, indicating that MRAP does not gradually 
flip but rather that a small amount of Nexo/Ccyt MRAP does not 
become fully glycosylated (Figure 5B).
To characterize MRAP topology in its natural setting, we 
took advantage of the OS3 line of mouse adrenal cells that does 
not express MC2 receptors. ACTH responses were measured 
in parallel in OS3 and CHO cells transfected with the cAMP 
reporter CRE-luciferase with or without MC2 receptor and 
MRAP (Figures 6A,B). ACTH stimulated a 26-fold increase in 
the cAMP response in CHO cells expressing MRAP and MC2 
receptor. Mock-transfected OS3 cells did not respond to ACTH, 
consistent with the reported absence of MC2 receptors (18). When 
the adrenal cells were transfected with MRAP and MC2 receptor, 
ACTH produced a striking 273-fold increase in cAMP reporter 
activity. OS3 cells must express MRAP, because MC2 receptors 
are functional when transfected alone. Interestingly, responses to 
forskolin were also exceptionally strong in OS3 cells. Forskolin 
acts directly on adenylyl cyclase and amplifies both basal and 
Gs-stimulated enzyme activity. Together, these findings suggest 
that adrenal OS3 cells have unusually efficient signal transduction 
at the G protein/adenylyl cyclase level.
We also explored MRAP orientation and the effects of MC2 
receptor and ACTH (Figures  6C,D). OS3 cells and parallel 
cultures of CHO cells were transfected with BirA and AP-tagged 
MRAPs with or without MC2 receptors and incubated overnight 
with or without 10  nM ACTH. For reasons that are not clear, 
expression of AP–MRAP was higher when MC2 receptor was 
co-expressed and that of MRAP–AP was lower. ACTH had little 
effect. Biotin labeled the non-glycosylated AP–MRAP band, as 
predicted if topology does not change. In OS3 cells, there was a 
non-specific biotin-labeled protein at ~37 kDa that did not cor-
respond to any MRAP band. MRAP–AP was weakly expressed in 
these cells and biotin-labeled species were partially obscured by 
the non-specific band.
is the MraP Protein stable?
Having established that MRAP topology is stable, we examined 
the overall stability of the accessory protein. The stability of 
MRAP was estimated in CHO cells stably expressing Flag-tagged 
MRAP together with GFP or MC2 receptor. Cultures were treated 
for 4 h with the protein synthesis inhibitor cycloheximide (CHX), 
the proteasome inhibitor MG132 or both (Figure  7A). MRAP 
was quite labile, with little protein remaining 4  h after protein 
synthesis blockade. Surprisingly, MG132 by itself caused an 
enormous increase in the concentration of MRAP. On the other 
hand, MG132 did little to protect MRAP from degradation when 
CHX was present. A similar pattern was seen with the MC2 
receptor, although the rate of degradation was slower (half-life 
between 3 and more than 8 h in different experiments) and effect 
of MG132 alone was much less marked. Mature MC2 receptor, 
which contains multiple sites for N-linked glycosylation (23, 24), 
ran as a broad band at high molecular weight, whereas immature 
core glycosylated and non-glycosylated receptor ran in more 
distinct bands close to the predicted molecular weight of 3xHA-
hMC2 receptor, 37.3  kDa. Figure  7B shows a similar experi-
ment demonstrating the rapidity of CHX and MG132 effects. 
The half-life of MRAP was estimated in similar experiments in 
which CHO cells were incubated with CHX from 0 to 5 h and 
MRAP levels were quantified densitometrically in immunoblots 
assuming first order kinetics. In most experiments, glycosylated 
MRAP was lost less rapidly than the non-glycosylated form, 
but this was not entirely consistent. The half-life of total MRAP 
averaged 1.7 ± 0.5 h (n = 7). The half-life of MRAP was short 
when it was transiently expressed with or without MC2 receptors 
in CHO cells but longer in adrenal OS3 cells, which grow less 
FigUre 4 | Only er-targeted Bira labels MraP on the outer surface of the plasma membrane. (a) CHO cells stably expressing BirAcyt or BirAER were 
grown on coverslips and transiently transfected with plasmids encoding AP–MRAP or MRAP–AP, each containing a Flag epitope in the C-terminal domain. Live cells 
were incubated with monoclonal anti-Flag epitope followed by Alexa488-labeled anti-mouse IgG (green) and Alexa555-labeled streptavidin (red), washed and 
imaged. Barely visible untransfected cells not expressing MRAPs demonstrate low background staining. (B) Schematic representation of Nexo/Ccyt and Ncyt/Cexo 
MRAPs before and after trafficking to the plasma membrane assuming that orientation does not change.
A
B
FigUre 5 | Kinetics of biotin labeling. CHO cells were transfected with BirAcyt and either (a) AP–MRAP or (B) MRAP–AP, both containing Flag epitope. After 
overnight incubation in medium without added biotin, 2.5 μM biotin was added for the times shown. MRAPs were immunoprecipitated with anti-Flag antibody, 
resolved on SDS-PAGE and blotted with either anti-Flag antibody, to identify total MRAP, or HRP–streptavidin, to identify biotin-labeled protein.
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rapidly than CHO cells (Figure 7C). To study turnover of MRAP 
on the plasma membrane, CHO cells were incubated for 1 h with 
protein synthesis or proteasome inhibitors and then either lysed 
or incubated with antibody to label cell surface MRAP selectively 
(Figure 7D). The effects of CHX and MG132 were not as extreme 
but clearly present when plasma membrane MRAP was isolated.
The use of a global protein synthesis inhibitor to study 
degradation of a particular protein is complicated by potential 
A C
B D
FigUre 6 | MraP orientation and function in chO and adrenal cells. (a) CHO and (B) OS3 adrenal cells were transfected with CRE-luciferase without 
(control) or with MRAP and MC2 receptor. The day after transfection cells were incubated for 5 h with vehicle, 1 μM ACTH or 20 μM forskolin when luciferase 
activity, expressed as relative light units (RLU), was measured. Note different scales for responses of OS3 and CHO cells. (c) CHO and (D) OS3 adrenal cells were 
transfected with BirAcyt and AP–MRAP or MRAP–AP containing Flag epitope with or without MC2 receptor. Cultures were incubated overnight with or without 10 nM 
ACTH. Lysates were run on SDS-PAGE and blots were incubated with anti-Flag antibody to detect total MRAP or HRP–streptavidin to detect biotin-labeled MRAP. 
In (D), the arrows point to a non-specific band, the solid arrowhead to non-glycosylated AP–MRAP, and the open arrowhead to glycosylated MRAP–AP. *P < 0.05 
vs. corresponding value in cells not expressing MC2R/MRAP.
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effects on proteins other than the one under study. To avoid this 
problem, we studied cells stably expressing cytoplasmic BirA 
and then measured the amount of biotinylated-MRAP–AP at 
intervals after the removal of extracellular biotin with or without 
addition of CHX (Figure 8). Since biotin cannot be removed from 
a protein until it has been thoroughly degraded, this approach is 
conceptually equivalent to a radiolabeling pulse-chase experi-
ment. For a low abundance protein, the method has the advantage 
of labeling only the protein of interest that can be concentrated 
on streptavidin beads prior to analysis. A limitation is the delay 
caused by the time required for washout of intracellular biotin. 
Following biotin withdrawal, total MRAP pools were quite stable 
over 20 h while normal synthesis and degradation were ongoing. 
The half-life of biotin-labeled MRAP was only 2.8  h, however, 
indicating that MRAP has a short half-life. In the presence of 
CHX, the corresponding values were 2.8 h for the total MRAP 
pool and 2.2 h for biotin-labeled MRAP. Because the half-lives 
measured by metabolic labeling and protein synthesis inhibition 
were strikingly similar, rapid turnover of MRAP was not an 
indirect effect of CHX.
In light of the effect of MG132, we investigated the possibility 
that MRAP itself undergoes ubiquitin-mediated degradation. 
In the canonical pathway ubiquitin is added to Lys residues and 
mouse MRAP has only four lysines, all located on the N-terminal 
side of the transmembrane helix in the juxtamembrane region. To 
test the importance of Lys to overall MRAP stability, we mutated 
these four residues to Arg (4K to R), retaining positive charge 
but removing lysine ɛ-amino groups that can be ubiquitylated. 
Arg-substituted MRAP was tagged with a V5 epitope on the 
N-terminus and a Flag epitope on the C-terminus, enabling anal-
ysis of its topology. Although (4K to R)MRAP was not expressed 
as highly as wild-type MRAP, it still assumed dual topology with 
both V5 and Flag epitopes on the plasma membrane (Figure 9A). 
Despite a lower level of MC2 receptor on the plasma membrane, 
cells expressing (4K to R)MRAP responded to ACTH with a 
cAMP increase equivalent to that supported by wild-type MRAP 
A C
DB
FigUre 7 | stability of MraP and Mc2 receptor. (a) CHO cells stably expressing Flag-tagged MRAP were transfected with either GFP or HA-tagged MC2 
receptor and then incubated for 4 h with no drug, 10 μg/ml cycloheximide (CHX), 50 μM MG132, or both. Cell lysates were run on SDS-PAGE and blotted for either 
(upper) MC2 receptor or (lower) MRAP. Brackets on the right show glycosylated MC2 receptor and core and non-glycosylated receptor. (B,D) CHO cells stably 
expressing Flag-tagged MRAP were incubated with 10 μg/ml cycloheximide (CHX), 50 μM MG132, or both for (B) times shown or (D) 1 h. In (B), cells were lysed 
and immunoprecipitation with anti-Flag antibody performed whereas in (D) cells were incubated for 15 min with1:1000 anti-Flag antibody and washed extensively 
before lysis and collection of Flag-labeled proteins on Protein A/G beads to isolate cell surface MRAP. (c) CHO and OS3 adrenal cells were transiently transfected 
with MRAP or MC2 receptor and MRAP, then incubated with 100 μg/ml cycloheximide for the times shown, lysed and blotted for MRAP.
A
B
FigUre 8 | half-life of biotinylated MraP is short with or without 
cycloheximide. (a,B) CHO cells stably expressing BirAcyt were transfected 
with MRAP–AP containing a Flag sequence, and incubated overnight in 
medium supplemented with biotin. Cells were then washed twice and 
incubated for 1–8 h in medium lacking biotin, (a) without or (B) with 10 μg/ml 
cycloheximide (CHX), when lysates were prepared and proteins resolved on 
SDS-PAGE and blots probed for either Flag epitope or biotin. The 
glycosylated form of MRAP–AP is labeled by cytoplasmic BirA.
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(Figure 9B). MG132 by itself caused an enormous increase in (4K 
to R)MRAP concentration just as it did with wild-type. Replacing 
all of the MRAP Lys residues with Arg delayed MRAP degrada-
tion by at most threefold (Figure 9C).
We tested whether ubiquitin is directly added to MRAP 
lysines by co-expressing HA-ubiquitin with either wild-type 
or (4K to R)MRAP in CHO cells and incubating for 3  h with 
MG132 to allow accumulation of any ubiquitylated species. 
Co-immunoprecipitation and immunoblotting revealed that Flag-
tagged MRAP undergoes ubiquitin modification (Figure 10A). 
Multiple ubiquitylated MRAP bands were observed and only one 
of them was lost in the Arg-substituted mutant, suggesting that 
ubiquitin is added to Lys and also to one of the amino acids less 
frequently ubiquitylated: the aminoterminal amino group, the 
hydroxyl group of Ser or Thr, or the sulfhydryl group of Cys (25). 
On average, ubiquitylated MRAP species totaled ~5% of total 
MRAP after incubation for 3 h with a proteasome inhibitor.
To rule out the possibility that MRAP ubiquitylation was 
occurring on one of the Lys residues in the Flag sequence, we 
tested AP–MRAP and AP-(4K to R)MRAP that contained the 
biotin acceptor peptide sequence but no epitope tag in cells 
expressing cytoplasmic BirA (Figure 10B). Once labeled with 
biotin, the AP tag has no lysine amino group available for ubiq-
uitin addition. Once again, multiple ubiquitylated MRAP bands 
were observed and only one was lost in the Arg-substituted 
10
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mutant, suggesting that ubiquitin was added to MRAP at an 
atypical site.
The glycosylation status of various MRAP bands was analyzed 
in lysates of cells expressing HA-Ub and MRAP before and after 
enzymatic deglycosylation with PNGaseF. None of the ubiquity-
lated MRAP bands was lost following PNGaseF treatment, whereas 
the slower-migrating MRAP bands collapsed to the mobility of 
the faster-migrating non-glycosylated species (Figure 11).
DiscUssiOn
The unusual antiparallel dimer structure of MRAP been described 
only for MRAP and its paralog MRAP2. These two proteins are 
evolutionarily ancient (26–28) and have retained features that 
result in dual topology, including highly conserved aminotermi-
nal and transmembrane domains and basic residues in the jux-
tamembrane region (29). The experiments described here do not 
explain what advantages are conferred by the conserved MRAP 
structure but they do establish that MRAP topology is stable from 
the time of MRAP biosynthesis to the time of MRAP degradation.
It has been particularly difficult to study MRAP topology 
because each side of the protein faces each direction in the 
antiparallel homodimer. Many of the methods used to assign 
membrane orientation require the addition of bulky fluorescent 
proteins or enzymes that are themselves larger than MRAP. Biotin 
labeling avoids this issue but has other drawbacks. Analysis of 
biotin-labeling patterns depended on the ability to distinguish 
between Nexo and Ncyt MRAPs based on glycosylation. Protein gly-
cosylation never reaches 100%, and in our experience the extent 
of MRAP glycosylation varies with MRAP species, epitope tags, 
and expression levels. In addition, some BirA activity appeared 
to remain in the cytoplasm when ER-targeted BirA was overex-
pressed. Finally, backgrounds on HRP–streptavidin blots tended 
to be high when low abundance proteins were being detected. 
Despite these limitations, some situations were unambiguous. 
Once it has left the ER and Golgi apparatus, MRAP cannot 
undergo further glycosylation. Once it has been biotinylated by 
cytoplasmic BirA, MRAP cannot be orientated with biotin facing 
the outside of the cell unless it flips. The important point is that 
changes in the orientation of MRAP were not observed in any of 
configurations examined.
When protein synthesis was blocked, MRAP protein levels 
declined with a half-life that varied in different experiments but 
averaged under 2 h. Use of biotin labeling to study MRAP stability 
was again instructive, confirming that rapid MRAP turnover was 
not an artifact of CHX treatment. Although it is not known how 
A B
C
FigUre 9 | importance of MraP lys residues for function, orientation, and stability. CHO cells were transfected with no accessory protein, wild-type 
MRAP or (4K to R)MRAP with the four native Lys residues mutated to Arg. (a) Surface expression of the N-terminal V5 and C-terminal Flag epitopes of MRAP and 
(4K to R)MRAP, and surface expression of co-transfected HA-tagged MC2 receptor. Results are normalized to values with wild-type MRAP. (B) cAMP responses to 
ACTH in cells co-transfected with MC2 receptor and CRE-luciferase. (c) Cells expressing MRAP or (4K to R)MRAP were incubated for the times shown with 
10 μg/ ml cycloheximide (CHX), 50 μM MG132 or both. Lysates were run on gels and blotted for Flag epitope. *P < 0.05 vs. corresponding value in cells expressing 
wild-type MRAP.
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quickly intracellular biotin declines when biotin is removed from 
the medium, this must happen quickly because biotin-labeled 
MRAP disappeared at roughly the same rate as total MRAP dur-
ing protein synthesis blockade. A biotin-labeling approach has 
the potential to measure the half-life of any protein that can be 
modified by the addition of a biotin ligase acceptor peptide. It 
avoids the cost and risk of radioisotopes, is applicable for proteins 
with amino acid compositions that render them unsuitable for 
35S-Met/Cys labeling, and can be used for proteins expressed at 
low abundance because of the ease of enriching on streptavidin 
beads.
Despite the presence of an array of chaperones that assist with 
protein folding in the ER, it is believed that a sizable fraction of 
newly synthesized protein fails to fold or assemble correctly. The 
accumulation of misfolded proteins in the ER can have disastrous 
outcomes, preventing synthesis of other membrane or secretory 
proteins. Cells contain elaborate and essential systems to remove 
terminally misfolded proteins from the ER, a process termed 
ER-associated degradation or ERAD (30, 31). ERAD involves 
recognition of misfolded protein, retrotranslocation from the 
ER, polyubiquitylation, and proteasomal degradation. Proteins 
are deglycosylated prior to degradation.
The involvement of proteasomal pathways in MRAP degrada-
tion was investigated here. One puzzling finding was that MG132 
caused a very striking increase in the amount of MRAP when 
protein synthesis was ongoing but provided almost no stabiliza-
tion when protein synthesis was blocked. Assuming that MG132 
effectively inhibited proteasome activity, the results indicate 
that an alternative pathway for MRAP degradation exists and is 
responsible for the majority of MRAP degradation. The ability of 
MG132 to increase MRAP may be explained if the proteasome 
inhibitor increases the efficiency of MRAP biosynthesis, perhaps 
by inducing molecular chaperones (32).
Although the results with MG132 suggest that proteasomal 
degradation is not the major pathway for MRAP turnover, 
ubiquitylated MRAP was detected following a 3-h incubation 
with MG132. One ubiquitylated MRAP band had a molecular 
weight 8–10 kDa higher than the comparable non-glycosylated 
MRAP band and was lost in Arg-substituted MRAP, indicating 
that it represents MRAP with a single ubiquitin added to a lysine. 
At least two heavier ubiquitylated MRAP bands were present in 
MRAP lacking any lysines and must, therefore, represent ubiqui-
tylation at some other amino acid but based on their migration on 
gels, these did not form a classical ubiquitin ladder. Cooray et al. 
demonstrated that MGRN1, an E3 ubiquitin ligase implicated in 
MC1 receptor function, is present in adrenal fasciculata and capa-
ble of adding ubiquitin to the MC2 receptor. They did not detect 
ubiquitylation of human MRAP in HEK293 cells in the absence of 
A B
FigUre 10 | MraP is ubiquitylated. (a) CHO cells were transfected with plasmids encoding GFP, Flag-tagged MRAP or (4K to R)MRAP, with or without 
HA-labeled ubiquitin (HA-Ub). After overnight incubation, cells were treated for 3 h with 50 μM MG132. MRAP proteins were immunoprecipitated with anti-Flag 
antibody and resolved on SDS-PAGE; blots were probed for HA. Asterisks mark IgG bands and black arrowheads show the position of the two MRAP bands from a 
parallel gel blotted for Flag. (B) CHO cells stably expressing cytoplasmic BirA were transfected with plasmids encoding GFP or AP–MRAP or AP-(4K to R)MRAP, 
both lacking any epitope tag, with or without HA-ubiquitin (HA-Ub). After overnight incubation in biotin-supplemented media, 50 μM MG132 was added for 3 h. 
Biotin-labeled proteins were collected on streptavidin beads and resolved on gels; blots were probed for HA. The arrowhead shows the position of biotin-labeled 
non-glycosylated AP–MRAP found on a parallel gel probed with streptavidin. The red arrows point to bands present in WT but not Lys-substituted MRAP. 
AP–MRAPs without epitope tags run at lower MWs than their longer tagged counterparts.
FigUre 11 | Major ubiquitylated MraP species are not glycosylated. 
CHO cells were transfected with HA-ubiquitin (HA-Ub) and wild-type or (4K to 
R)MRAPs, which contained Flag epitopes. After overnight incubation cultures 
were treated for 3 h with 50 μM MG132 when lysates were prepared. 
Flag-tagged proteins were immunoprecipitated and treated with or without 
PNGaseF, which collapsed the slower-running glycosylated MRAP and (4K to 
R)MRAP bands. Asterisks show IgG bands. With longer exposure, higher 
MW bands were visible in the anti-Flag blot but obscured by the major MRAP 
bands. Red arrows point to ubiquitin-labeled bands present in WT but not 
Lys-substituted MRAP.
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